,,

產(chǎn)品搜索

產(chǎn)品分類(lèi)

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話(huà)：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73202LMNA-NTRK1/BaF3

名稱(chēng)	LMNA-NTRK1/BaF3
型號(hào)	CBP73202
報(bào)價(jià)
特點(diǎn)	LMNA-NTRK1/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO

詳細(xì)內(nèi)容

CBP73202
I. Introduction
Cell Line Name：	LMNA-NTRK1/BaF3
Host Cell:	BA/F3
Stability:	16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application:	Anti-proliferation assay and PD assay
Freeze Medium:	90% FBS+10% DMSO
Complete Culture Medium:	RPMI-1640+10%FBS+2ug/ml puromycin
Mycoplasma Status:	Negative

II.Background
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)

III. Representative Data
1. WB of LMNA-NTRK1/BaF3 expression



2. Sanger of LMNA-NTRK1/BaF3 expression Figure 2. Sanger Sequencing of LMNA-NTRK1/BaF3
3. Anti-proliferation assay

Figure 3. Anti-proliferation assay of two reference compounds on the LMNA-NTRK1/BaF3 Stable Cell Line